The role of immune-related adverse events (irAEs), as a surrogate predictor of the efficacy of checkpoint inhibitors, has not yet been described in the setting of first-line, single-agent pembrolizumab for patients with metastatic non-small-cell lung-cancer (NSCLC) with a programmed death-ligand 1 (PD-L1) expression of ≥ 50%.
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes / Cortellini, A., Friedlaender, A., Banna, G.L., Porzio, G., Bersanelli, M., Cappuzzo, F., Aerts, J.G.J.V., Giusti, R., Bria, E., Cortinovis, D., Grossi, F., Migliorino, M.R., Galetta, D., Passiglia, F., Berardi, R., Mazzoni, F., Di Noia, V., Signorelli, D., Tuzi, A., Gelibter, A., et al.. - In: CLINICAL LUNG CANCER. - ISSN 1525-7304. - STAMPA. - 21:(2020), pp. 498-508. [10.1016/j.cllc.2020.06.010]
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes
Antonuzzo, Lorenzo;
2020
Abstract
The role of immune-related adverse events (irAEs), as a surrogate predictor of the efficacy of checkpoint inhibitors, has not yet been described in the setting of first-line, single-agent pembrolizumab for patients with metastatic non-small-cell lung-cancer (NSCLC) with a programmed death-ligand 1 (PD-L1) expression of ≥ 50%.
| File | Dimensione | Formato | |
|---|---|---|---|
|
j.cllc.2020.06.010.pdf
accesso aperto
Tipologia:
Versione finale referata (Postprint, Accepted manuscript)
Licenza:
Tutti i diritti riservati
Dimensione
692.94 kB
Formato
Adobe PDF
|
692.94 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
